FDAmanufacturing / CMC66% confidence
CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative
Source: FDA
Why This Matters
Why this matters: provides agency context on manufacturing / CMC that may shape timing or evidence expectations for Novartis; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · MEK Inhibitor
- Sub-indication
- General
Related signal: FDA Accepts Supplement for Mekinist (Trametinib) by Novartis